Antibody therapies work in part by binding to Fc receptors, proteins found on immune cells that control key immune functions such as antibody-mediated cell killing and inflammation. Since these ...

In the world of biomedical research, the humble lab mouse is a superstar—it’s easy enough to rear in large quantities, shares a considerable amount of core biological processes with humans, and is ...

In recent months, the Food and Drug Administration and National Institutes of Health have announced new initiatives to reduce and replace animal testing in biomedical research. Central to these ...

Genetically altered mice are valuable tools in biomedical research. The Mutant Mouse Resource and Research Center, located at UC Davis and supported by a grant from NIH, has been providing a national ...

A fundamental challenge in preclinical research is accurately predicting human responses using conventional animal models. Traditional approaches often fail to adequately model human disease, creating ...

Researchers are working to create the first strain of mice that's genetically susceptible to late-onset Alzheimer's, with potentially transformative implications for dementia research. Mice don't get ...

One of those genes encodes the enzyme DHDDS, part of the pathway that glycosylates proteins in higher cells. Retinitis pigmentosa from DHDDS mutations is called RP59. This is a recessive genetic ...

This database provides information about selected rodent models of neurodegenerative disease, including Alzheimer’s, Parkinson’s, and ALS. By summarizing, visualizing, and continuously updating ...

Why Antibody Therapies Fail in Late-Stage Testing. Antibody therapies work in part by binding to Fc? receptors, proteins ...